CJC-1295 With DAC and Without DAC
“With DAC” and “without DAC” point to a molecular modification question. They should not be treated as interchangeable suffixes on the same fully defined product. Resolve the exact sequence, linker and terminal chemistry before assigning a reference mass or literature finding.
Ask for the structure behind the label
| Label on a record | What still needs confirmation |
|---|---|
| CJC-1295 with DAC | Exact backbone, reactive modification and supplied form |
| CJC-1295 without DAC | Exact intended entity, sequence and terminal chemistry |
| CJC-1295 alone | Whether the modification is present at all |
The albumin-linked GRF study and the long-acting CJC-1295 human study concern defined modified constructs. Their findings cannot resolve an unspecified supplier label. [1] [2]
Compare the analytical expectation
Once the entity is defined, the expected identity result must match that structure and the method used. A report should not alternate between variant names while presenting one unexplained expected mass. Ask the issuer to reconcile any such inconsistency.
In an original fictional example, a specification names a modified construct while a report names an unmodified one. Preserve both descriptions and request a correction or documented explanation. A favourable purity result does not close the identity conflict.
Read each supplied document with the Certificate of Analysis guide so the reported identity and method are not replaced by an assumption about the product name.
The catalogue blend remains a separate decision
The CJC component of the CJC/ipamorelin blend needs its variant confirmed. Until then, no exact CJC molar mass or modified-construct half-life is assigned to that component here.
Use CJC-1295 for the molecular record, names and identifiers for reconciliation and mass spectrometry for interpreting the measurement. This comparison provides no dosing interval or claim of clinical equivalence between variants.
Follow the comparison
| Resource | Why open it |
|---|---|
| Half-Life Modification: DAC, Acylation and Conjugation | Distinguish molecular modification from a storage-life claim. |
| Sterility, Endotoxin and Bioburden Are Three Different Things | Separate sterility, endotoxin and bioburden evidence. |
| Batch Reports and Certificate Library | Request the document for the relevant product and lot. |
| Product Specification and Identity Standards | Check which tests, criteria and quantity basis a specification defines. |
| Compound Comparisons | Choose a comparison by its specific identity question. |
Sources and scope
- Jetté et al. (2005). Albumin-linked GRF analogues in rats. Endocrinology.Albumin-reactive construct is essential to identity; no half-life transfer to unresolved/no-DAC material. Access: Original article abstract retrieved through official Europe PMC core record
- Teichman et al. (2006). Long-acting CJC-1295 in healthy adults. JCEM.Two healthy-adult trials of long-acting construct; 5.8–8.1-day half-life is not storage stability or a blend protocol. Access: Original article abstract retrieved through official Europe PMC core record